Medicortex International publishes company presentation
Medicortex International publishes company presentation
Medicortex International AB (publ) today publishes an updated company presentation. The presentation will be used in meetings with investors and other stakeholders, and is being published so that all market information is available to all shareholders at the same time.
The presentation describes the group following the acquisition of Medicortex Finland Oyj. It covers the need for better diagnostics for traumatic brain injury and concussion, the company's urine-based rapid test ProbTBI® and the saliva-based test in development. It also outlines the planned product timeline, the market, the competitive landscape, the patent portfolio, funding history and the group's holdings as of 30 September 2026.
"We want all shareholders to have the same picture of Medicortex as the investors we meet. The presentation gives a complete overview of where we stand today and the path towards a finished test for brain injury," says Adrian Harel, CEO of Medicortex International AB (publ).
The presentation is attached to this press release and will also be made available on the company's website, medicortex.eu.